Abstracts Archive - Page 2111 of 2607 - ACR Meeting Abstracts

Abstract Number: 1838 • 2014 ACR/ARHP Annual Meeting
No Increased Risk of Developing a First Invasive Melanoma in Rheumatoid Arthritis Patients Treated with Biologics: Results of a Collaborative Project of 11 European Biologics Registers
Louise Mercer¹, Johan Askling², Pauline Raaschou³, William Dixon¹, Lene Dreyer⁴, Merete Lund Hetland⁵, Lene Mellemkjær⁶, Anja Strangfeld⁷, Angela Zink⁸, Florenzo Iannone⁹, Axel Finckh¹⁰, Jakub Zavada¹¹, Helena Canhao¹², Fernando Martins¹³, Xavier Mariette¹⁴, Jacques Morel¹⁵, Jacques-Eric Gottenberg¹⁶, Adele Green¹, Victoria Hernández¹⁷, Florence Tubach¹⁸, Piet van Riel¹⁹, Kimme Hyrich²⁰ and Joachim Listing⁷, ¹The University of Manchester, Manchester, United Kingdom, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Copenhagen University Hospital at Gentofte, Gentofte, Denmark, ⁵On behalf of all Depts of Rheumatology in Denmark, DANBIO, Glostrup Hospital, Glostrup, Denmark, ⁶Virus, Lifestyle and Genes, The Danish Cancer Society, Copenhagen, Denmark, ⁷German Rheumatism Research Center, Berlin, Germany, ⁸German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ⁹Reumatologia Universita e Policlinico di Bari, Bari, Italy, ¹⁰Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ¹¹Charles University, Prague, Czech Republic, ¹²Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, ¹³Instituto de Medicina, Universidade de Lisboa, Lisbon, Portugal, ¹⁴rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ¹⁵Universite´ Montpellier, Montpellier, France, ¹⁶Department of rheumatology CHU, Strasbourg, France, ¹⁷BIOBADASER Registry, Madrid, Spain, ¹⁸INSERM, Universite Paris Diderot, Paris, France, ¹⁹Radboud University Medical Centre, Nijmegen, Netherlands, ²⁰Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Swedish and Danish national biologics registers (*) have reported a possible increase in melanoma risk with TNF inhibitors. Since melanomas are uncommon, the association…
Abstract Number: 1837 • 2014 ACR/ARHP Annual Meeting
First Results of a European Registries Collaborative Project to Compare the Spectrum of Lymphomas Between Different Exposure Groups in Rheumatoid Arthritis
Louise Mercer¹, Xavier Mariette², William Dixon¹, Eva Baecklund³, Karin Hellgren⁴, Lene Dreyer⁵, Merete Lund Hetland⁶, Lene Mellemkjær⁷, Kimme Hyrich⁸, Anja Strangfeld⁹, Angela Zink¹⁰, Helena Canhao¹¹, Fernando Martins¹², Victoria Hernández¹³, Florence Tubach¹⁴, Jacques-Eric Gottenberg¹⁵, Jacques Morel¹⁶, Jakub Zavada¹⁷, Piet van Riel¹⁸, Axel Finckh¹⁹, Florenzo Iannone²⁰, Johan Askling²¹ and Joachim Listing²², ¹The University of Manchester, Manchester, United Kingdom, ²rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ³Uppsala University, Uppsala, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Copenhagen University Hospital at Gentofte, Gentofte, Denmark, ⁶On behalf of all Depts of Rheumatology in Denmark, DANBIO, Glostrup Hospital, Glostrup, Denmark, ⁷Virus, Lifestyle and Genes, The Danish Cancer Society, Copenhagen, Denmark, ⁸Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ¹⁰German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ¹¹Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, ¹²Instituto de Medicina, Universidade de Lisboa, Lisbon, Portugal, ¹³BIOBADASER Registry, Madrid, Spain, ¹⁴INSERM, Universite Paris Diderot, Paris, France, ¹⁵Department of rheumatology CHU, Strasbourg, France, ¹⁶Universite´ Montpellier, Montpellier, France, ¹⁷Charles University, Prague, Czech Republic, ¹⁸Radboud University Medical Centre, Nijmegen, Netherlands, ¹⁹Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ²⁰Reumatologia Universita e Policlinico di Bari, Bari, Italy, ²¹Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ²²German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is associated with a 2-3 fold increased risk of both Hodgkin and non-Hodgkin lymphoma (HL; NHL). The risk of lymphoma, in…
Abstract Number: 1836 • 2014 ACR/ARHP Annual Meeting
Safety of Zoster Vaccination Administration in Rheumatic Patients on Current Biologic Therapy
Stephen Lindsey¹, Brandi Oufnac² and Holly Walker², ¹Chief Div of Rheumatology, Ochsner Clinic Baton Rouge, Baton Rouge, LA, ²Rheumatology, Ochsner Health Systems, Baton Rouge, LA
Background/Purpose Herpes Zoster (HZ) occurs in 1 in 3 people in the U.S. during their lifetime. The greatest risk factor is age. Immune suppression from…
Abstract Number: 1835 • 2014 ACR/ARHP Annual Meeting
Anti-Osteoporosis Medication Use after Hip or Vertebral Fracture
Robert A. Overman¹ and Chad L. Deal², ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Current National Osteoporosis Guidelines recommend treatment with an approved osteoporosis medication after hip and vertebral fracture. Only 20% of patients receive osteoporosis therapy after…
Abstract Number: 1834 • 2014 ACR/ARHP Annual Meeting
Uptake of the American College of Rheumatology’s (ACR) Rheumatology Clinical Registry (RCR): Quality Measure Summary Data
Natalie Fisk¹, Melissa Francisco², Jinoos Yazdany³ and Salahuddin Kazi⁴, ¹Registry, American College of Rheumatology, Atlanta, GA, ²American College of Rheumatology, Atlanta, GA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Internal Medicine/Rheumatology, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The RCR is designed to provide ACR members with an infrastructure for quality reporting related to rheumatoid arthritis, gout, osteoarthritis, osteoporosis, and drug safety.…
Abstract Number: 1833 • 2014 ACR/ARHP Annual Meeting
Quality of Primary Care Management of Patients with and without Rheumatoid Arthritis (RA)
Jessica Widdifield¹, Claire Bombardier², Jacqueline Young¹, Noah Ivers³, R. Liisa Jaakkimainen⁴, Sasha Bernatsky⁵, J. Michael Paterson¹, J. Carter Thorne⁶, Pooneh S.Akhavan⁷, Debra Butt¹, Vandana Ahluwalia⁸ and Karen Tu¹, ¹Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁵Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁶Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸William Osler Health Center, Brampton, ON, Canada
Background/Purpose: Little is known about the quality of care received by patients with multiple chronic conditions in primary care and whether quality care is different…
Abstract Number: 1830 • 2014 ACR/ARHP Annual Meeting
A Novel Population Care Model in Rheumatoid Arthritis – Significant Improvement in Quality and Reduction in Cost of Care
Eric D. Newman¹, William T. Ayoub², David M. Pugliese³, Chelsea Cedeno⁴, Jason Brown⁵, Thomas M. Harrington⁶, Thomas P. Olenginski⁶, Androniki Bili⁷, Alfred E. Denio⁶, Lisa L. Schroeder⁷, Dennis Torretti⁷, Tarun Sharma⁷, Lyudmila Kirillova⁷, Susan Mathew⁷, Jonida Cote⁷, Brian Oppermann², Cynthia Sullivan², Shantanu Bishwal⁸, Brian DelVecchio³ and Howard Aylward⁹, ¹Department of Rheumatology, Geisinger Health System, Danville, PA, ²Rheumatology, Geisinger Health System, State College, PA, ³Rheumatology, Geisinger Health System, Wilkes-Barre, PA, ⁴Division of Medicine, Geisinger Medical Center, Geisinger Health System, Danville, PA, ⁵Henry Hood Center for Clinical Research, Geisinger Health System, Danville, PA, ⁶Dept of Rheumatology, Geisinger Health System, Danville, PA, ⁷Rheumatology, Geisinger Health System, Danville, PA, ⁸Rheumatology, Geisinger Health System, Wilkes Barre, PA, ⁹Geisinger Health System, State College, PA
Background/Purpose: Rheumatoid arthritis (RA) is a common chronic disease with significant morbidity, mortality, and cost. To optimize care for RA patients, we developed a novel…
Abstract Number: 1831 • 2014 ACR/ARHP Annual Meeting
Monitoring Patients with Rheumatoid Arthritis in Routine Care – Experiences from a Treat-to-Target Strategy Using the Danbio Registry
Merete Lund Hetland¹, Dorte Vendelbo Jensen² and Niels Steen Krogh³, ¹On behalf of all Depts of Rheumatology in Denmark, DANBIO, Glostrup Hospital, Glostrup, Denmark, ²DANBIO, Glostrup, Denmark, ³ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: Monitoring patients with rheumatoid arthritis (RA) in clinical practice with regular assessment of disease activity (e.g. DAS28) is recommended as a part of a…
Abstract Number: 1832 • 2014 ACR/ARHP Annual Meeting
National Quality Forum Measure Achievement and Costs in Rheumatoid Arthritis Patients in a Large Managed Care Population
Roxanne Meyer¹, Susan C. Bolge², Joseph Tkacz³, Brenna Brady³ and Charles Ruetsch⁴, ¹Janssen Scientific Affairs, Horsham, PA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Health Analytics, LLC, Columbia, MD, ⁴Health Analytics LLC, Columbia, MD
Background/Purpose: The American College of Rheumatology and National Quality Forum (NQF) recommend monitoring quality measures among rheumatoid arthritis (RA) patients. Previously we described the proportion…
Abstract Number: 1829 • 2014 ACR/ARHP Annual Meeting
Role of Fluorinated Steroids in Preventing the Progression of Anti-SSA/Ro Associated Isolated Congenital Heart Block to Disease Beyond the Conduction System
Ummara Shah¹, Amit Saxena¹, Sara Sahl², Deborah Friedman³, Jill P. Buyon¹ and Peter M. Izmirly², ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: The cardiac manifestations of neonatal lupus (cardiac NL) characteristically present as conduction disease. A major concern is the extension of injury beyond the AV…
Abstract Number: 1828 • 2014 ACR/ARHP Annual Meeting
Adverse Pregnancy Outcomes in Adolescents and Young Women with Systemic Lupus Erythematosus: A National Estimate
Nicole Ling¹, Isabel E. Allen², Erica F. Lawson¹ and Emily von Scheven³, ¹Pediatrics, University of California, San Francisco, San Francisco, CA, ²Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ³Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Pregnant women with SLE have increased risk of adverse outcomes including lupus flare, spontaneous abortion, preeclampsia/eclampsia, premature birth and maternal death, but pregnancy outcomes…
Abstract Number: 1827 • 2014 ACR/ARHP Annual Meeting
Anti-Ro and Anti-La Antibodies in the General Pregnant Population
Evelyn V. Rozenblyum¹, Sharon Sukhdeo², Edgar Jaeggi³, Lisa Hornberger⁴, Philip Wyatt⁵, Carl A. Laskin⁶ and Earl D. Silverman⁷, ¹Pediatrics, University of Toronto, Toronto, ON, Canada, ²Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ³Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴Pediatric Cardiology , Tel: 780-407-3355; Fax: 780-407-3954;, Stollery Children's Hospital, Edmonton, ON, Canada, ⁵Department of Genetics, North York General Hospital, Toronto, ON, Canada, ⁶University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose Neonatal lupus erythematosus (NLE) is a passively transferred autoimmune disease that occurs in babies born to pregnant women with anti-Ro and anti-La antibodies. The…
Abstract Number: 1846 • 2014 ACR/ARHP Annual Meeting
The Association Between Hydroxychloroquine Treatment and Cardiovascular Morbidity Among Rheumatoid Arthritis Patients
Michael Shapiro¹ and Yair Levy², ¹Haim Lebanon 55, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Internal Medicine E, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Accelerated atherosclerosis and cardiovascular disease are the main causes of mortality in Rheumatoid Arthritis (RA). The anti-malarial drug Hydroxychloroquine (HCQ) has long been used…
Abstract Number: 1845 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ricardo Blanco⁶, Ariella Kelman⁷, Sophie Dimonaco⁸ and Nina Mitchell⁸, ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Hospital Marques de Valdecilla, Santander, Spain, ⁷Genentech, South San Francisco, CA, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Treatment with tocilizumab (TCZ) in combination with MTX or as monotherapy (Mono) in MTX-naive patients (pts) with early RA resulted in improved signs and…
Abstract Number: 1844 • 2014 ACR/ARHP Annual Meeting
Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data
Jeffrey R. Curtis¹, Melvin Churchill², Alan Kivitz³, Laura Gauer⁴, Christopher Herrem⁴, David Carter⁵, Jeffrey Melin⁴ and Yusuf Yazici⁶, ¹The University of Alabama at Birmingham, Birmingham, AL, ²Arthritis Center of Nebraska, Lincoln, NE, ³Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Brussels, Belgium, ⁶New York University Hospital for Joint Diseases, New York, NY
Background/Purpose The PREDICT trial (NCT01255761) examined predictability of certolizumab pegol (CZP) treatment success at Week (Wk) 52 based on response at Wk12 assessed by RAPID3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].